Glenmark Q4 misses estimates but charts suggest upside: Analyst

Glenmark Pharmaceuticals shares declined 3% on Monday after the company reported fourth-quarter earnings that fell short of street expectations, despite delivering a significant turnaround from last year's losses. Technical charts hint at a bullish breakout if the ₹1,554 level is breached, according to advisor A&Y Market Research.